Celltrion announced on the 7th that Seo Jin-seok, CEO of the Business Management Division, and Executive Vice President Lee Hyuk-jae will attend the “2026 JP Morgan Healthcare Conference (JPM),” the world’s largest pharmaceutical and biotech investment event, to present the company’s new drug development achievements and future contract manufacturing organization (CMO) business strategy.

Marking its 44th year, JPM is the world’s largest biotech investment conference, attracting a large number of global pharmaceutical and biotechnology companies and investors. This year as well, it is reported that more than 8,000 global investors and industry officials will participate.

Celltrion stated that, following last year, it has again been selected as a presenter in the event’s core program, the main track, and plans to give its presentation in the hotel grand ballroom at 3:45 p.m. on the 13th. The main track is known as a stage to which only a select group of companies, whose standing and growth potential in the global biotech industry have been recognized, are invited.

According to Celltrion, CEO Seo plans to present a mid- to long-term new drug development roadmap based on the new drug pipeline development schedule first disclosed last year, incorporating development results to date as well as previously undisclosed new pipelines. In the biosimilar segment, the company will also present a phased product launch schedule and a strategy to expand its global target markets, and plans to hold a Q&A session with global investors after the presentation.

Executive Vice President Lee will then unveil a strategy to establish an end-to-end U.S. supply chain centered on the recently acquired production facility in Branchburg, New Jersey, and outline plans to expand the CMO business based on this platform.

Celltrion explained that, leveraging the technology and development know-how accumulated through the development of the world’s first antibody biosimilar, it is accelerating antibody-based new drug development, including antibody-drug conjugates (ADCs) and multispecific antibodies, while at the same time using its U.S. production facility to mitigate tariff risks and strengthen the stability of its global supply.

The industry expects that, through this JPM, investor attention will focus on Celltrion’s competitiveness in its new drug pipeline, its biosimilar product expansion strategy, and its global manufacturing and supply capabilities.

A Celltrion official said, “Through this presentation, the company plans to present in more concrete terms its strategies to sustain its future revenue growth trajectory, focusing on new product expansion and the CMO business alongside its new drug development achievements,” adding, “By combining competitive antibody technologies with global manufacturing capabilities, the company intends to clearly communicate to investors its business direction for achieving sustainable growth.”

Popular News